CureVac N.V.

-0.49 (-0.60%)
Earnings Announcements

Curevac - Quality Of Immune Response Was Found To Be Comparable To Recovered COVID-19 Patients

Published: 11/10/2020 12:09 GMT
(CVAC) - Curevac : Curevac Publishes Detailed Interim Phase 1 Data of Its Covid-19 Vaccine Candidate, Cvncov.
Data Publication Follows Positive Topline Data Reported November 2, 2020.
Full Pre-print Manuscript Available on Medrxiv.
Quality of Immune Response Was Found to Be Comparable to Recovered Covid-19 Patients, Closely Mimicking Immune Response After Natural Covid-19 Infection.
Previously Announced Interim Data Showed That Cvncov Was Generally Well Tolerated Across All Tested Doses (2-12Μg) and Induced Strong Binding and Neutralizing Antibody Responses in Addition to First Indication of T Cell Activation.
Revenue is expected to be $62.96 Million
Adjusted EPS is expected to be -$0.41

Next Quarter Revenue Guidance is expected to be $45.58 Million
Next Quarter EPS Guidance is expected to be -$0.62

More details on our Analysts Page.